A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

19991,596 citationsJournal Articlebronze Open Access

Authors

M Samama · Hôtel-Dieu de Paris

Alexander T. Cohen · St. George's School

Jean‐Yves Darmon

Louis Desjardins · Centre hospitalier universitaire de Québec

Amiram Eldor · Tel Aviv Sourasky Medical Center

C Janbon · Hôpital Saint Eloi

Alain Leizorovicz · Université Claude Bernard Lyon 1

Abstract

Prophylactic treatment with 40 mg of enoxaparin subcutaneously per day safely and effectively reduces the risk of venous thromboembolism in patients with acute medical illnesses.

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Atrial Fibrillation Management and Outcomes Acute Myocardial Infarction Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 341, Issue 11, pp. 793-800

DOI: 10.1056/nejm199909093411103

Field-Weighted Citation Impact: 28.96